Michael Austwick insider trades: Verona Pharma (VRNA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Michael reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 1, 2025 | VRNA | ↓ Sell | 11,288 | $13.14 | $148K | Direct | Aug 5, 2025 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Michael Austwick's insider trades
Michael Austwick is a director at Verona Pharma (VRNA). Since Aug 1, 2025, Michael has reported no open-market purchases and 1 sale worth $148K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include option exercises (2 filings), grants and awards (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VRNA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.